ECSP088387A - Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms - Google Patents

Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms

Info

Publication number
ECSP088387A
ECSP088387A EC2008008387A ECSP088387A ECSP088387A EC SP088387 A ECSP088387 A EC SP088387A EC 2008008387 A EC2008008387 A EC 2008008387A EC SP088387 A ECSP088387 A EC SP088387A EC SP088387 A ECSP088387 A EC SP088387A
Authority
EC
Ecuador
Prior art keywords
kinase
fms
inhibition method
subject
present
Prior art date
Application number
EC2008008387A
Other languages
English (en)
Inventor
Carl Illig
Shelley Ballentine
Jinsheng Chen
Sanath Meegalla
M Jonathan Rudolph
Mark Wall
Christian Andrew Baumann
Robert W Tuman
Dana L Johnson
Kenneth Wilson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP088387A publication Critical patent/ECSP088387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Un método para reducir o inhibir la actividad de cinasa de FLT3 en una célula o un sujeto, y el uso de dichos compuestos para prevenir o tratar en un sujeto un trastorno proliferativo de células y/o trastornos relacionados con FLT3 usando un compuesto de la presente invención (I)o solvato, hidrato, tautómero o sal farmacéuticamente aceptable del mismo; la presente invención además está dirigida a métodos para tratar condiciones como cánceres y otros trastornos proliferativos de células.
EC2008008387A 2005-10-18 2008-04-18 Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms ECSP088387A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72768705P 2005-10-18 2005-10-18

Publications (1)

Publication Number Publication Date
ECSP088387A true ECSP088387A (es) 2008-05-30

Family

ID=37864477

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008387A ECSP088387A (es) 2005-10-18 2008-04-18 Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms

Country Status (19)

Country Link
US (1) US7795279B2 (es)
EP (1) EP1951234A2 (es)
JP (2) JP2009511628A (es)
KR (1) KR101443651B1 (es)
CN (1) CN101340909B (es)
AU (1) AU2006304897B2 (es)
BR (1) BRPI0617489A2 (es)
CA (1) CA2626623C (es)
CR (1) CR9984A (es)
EA (1) EA200801118A1 (es)
EC (1) ECSP088387A (es)
GT (1) GT200800042A (es)
IL (1) IL190727A (es)
NO (1) NO20082223L (es)
NZ (1) NZ595182A (es)
SV (1) SV2008002880A (es)
UA (1) UA94719C2 (es)
WO (1) WO2007048088A2 (es)
ZA (1) ZA200804253B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846630B2 (en) * 1996-10-18 2005-01-25 Takara Shuzo Co., Ltd. Nucleic acid encoding receptor type protein kinase
PT1807077T (pt) * 2004-10-22 2017-01-06 Janssen Pharmaceutica Nv Inibidores de quinase c-fms
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006304897B2 (en) * 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
WO2007104053A2 (en) * 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
WO2007124319A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
PL2021335T3 (pl) * 2006-04-20 2011-10-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory kinazy C-FMS
CA2649755C (en) 2006-04-20 2014-12-02 Janssen Pharmaceutica N.V. Method of inhibiting c-kit kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
HUE045270T2 (hu) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
US20130156764A1 (en) * 2010-03-12 2013-06-20 The Johns Hopkins University Neutralization of flt3 ligand as a leukemia therapy
BR112014007622A2 (pt) 2011-09-30 2017-04-04 Oncodesign Sa inibidores de flt3 cinase macrocíclicos
CN104870454B (zh) 2012-08-07 2020-03-03 詹森药业有限公司 用于制备杂环酯衍生物的方法
ES2658773T3 (es) 2012-08-07 2018-03-12 Janssen Pharmaceutica N.V. Procedimiento de sulfonilación usando fluoruro de nonafluorobutanosulfonilo
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
JP6330040B2 (ja) 2013-07-22 2018-05-23 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−（ピペラジン−１−イル）−２−（［１，２，４］トリアゾール−１−イル）−エタノン誘導体
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
BR112017002001B1 (pt) * 2014-07-31 2022-10-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compostos e composição farmacêutica
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
PL3245203T3 (pl) 2015-01-15 2019-05-31 Idorsia Pharmaceuticals Ltd Pochodne hydroksyalkilopiperazyny jako modulatory receptora cxcr3
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
JP2020519665A (ja) 2017-05-17 2020-07-02 アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル） オピオイドによる痛みの処置を改善する為のｆｌｔ３阻害剤
US11331313B2 (en) 2017-05-22 2022-05-17 Whitehead Institute For Biomedical Research KCC2 expression enhancing compounds and uses thereof
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
RU2020109328A (ru) 2017-08-04 2021-09-06 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US6852752B2 (en) * 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
ATE303998T1 (de) 2000-10-17 2005-09-15 Merck & Co Inc Oral aktive salze mit tyrosinkinaseaktivität
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
EP1458713B1 (en) 2001-12-27 2005-08-24 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
DE60326646D1 (de) 2002-12-18 2009-04-23 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
US7427683B2 (en) 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
US20050113566A1 (en) 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
MXPA05011503A (es) * 2003-04-25 2006-05-31 Johnson & Johnson Inhibidores de la c-fms cinasa.
PT1807077T (pt) * 2004-10-22 2017-01-06 Janssen Pharmaceutica Nv Inibidores de quinase c-fms
US20060281771A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006304897B2 (en) * 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
MX2008005814A (es) * 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
US20070179125A1 (en) * 2005-11-16 2007-08-02 Damien Fraysse Aminopyrimidines useful as kinase inhibitors

Also Published As

Publication number Publication date
KR101443651B1 (ko) 2014-09-23
ZA200804253B (en) 2009-11-25
UA94719C2 (ru) 2011-06-10
GT200800042A (es) 2008-11-03
AU2006304897A1 (en) 2007-04-26
EA200801118A1 (ru) 2008-10-30
AU2006304897B2 (en) 2012-07-12
JP2009511628A (ja) 2009-03-19
CA2626623A1 (en) 2007-04-26
IL190727A (en) 2015-05-31
CA2626623C (en) 2016-08-30
CN101340909A (zh) 2009-01-07
NZ595182A (en) 2012-12-21
US7795279B2 (en) 2010-09-14
SV2008002880A (es) 2010-01-05
US20070149572A1 (en) 2007-06-28
CN101340909B (zh) 2012-01-11
KR20080064867A (ko) 2008-07-09
EP1951234A2 (en) 2008-08-06
JP2014129407A (ja) 2014-07-10
BRPI0617489A2 (pt) 2011-07-26
WO2007048088A3 (en) 2007-06-07
NO20082223L (no) 2008-07-02
CR9984A (es) 2008-09-09
IL190727A0 (en) 2008-12-29
WO2007048088A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
ECSP088387A (es) Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms
MX2021003517A (es) Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
TNSN08088A1 (en) Substituted benzimidazoles as kinase inhibitors
CO6382175A2 (es) Metodo para inhibir la cinasa del c-kit
CR10419A (es) Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
SG166827A1 (en) Aminopyrimidines useful as kinase inhibitors
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2007149427A3 (en) Tyrosine kinase inhibitors
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
UA98297C2 (en) Triazolopyridazines as tyrosine kinase modulators
EA201000093A1 (ru) Производные пиридазинона
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей
DK1896421T3 (da) Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MX2009002842A (es) Inhibidores heterociclicos de c-met y usos de los mismos.
ECSP078017A (es) Inhibidores de tirosina quinasa
ATE542814T1 (de) Pyrazinkinaseinhibitoren
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
TW200745088A (en) Benzimidazoles useful as inhibitors of protein kinases